Synonym: CD33 antigen-like 3, SIGLEC-15, CD33L3, sialic acid-binding Ig-like lectin 15, Siglec15, Siglec-15
Source: Cynomolgus Siglec-15, His Tag (SG5-C52H6) is expressed from human 293 cells (HEK293). It contains AA Phe 20 - Thr 263 (Accession # A0A2K5UY47-1).
Predicted N-terminus: Phe 20
Less than 1.0 EU per μg by the LAL method.
Purity: >90% as determined by SDS-PAGE.
Formulation: Lyophilized from 0.22 μm filtered solution in PBS with Arginine, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Reconstitution: Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 28.1 kDa. The protein migrates as 30-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
For long term storage, the product should be stored at lyophilized state at -20 °C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
- 4-8 °C for 12 months in lyophilized state;
- -70 °C for 3 months under sterile conditions after reconstitution.
Cynomolgus Siglec-15, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Cynomolgus Siglec-15, His Tag (Cat. No. SG5-C52H6) at 5 μg/mL (100 μL/well) can bind Mouse Human chimeric MAb (5G12, Human IgG1) with a linear range of 0.3-2 ng/mL (QC tested).
Siglec-15 is a DAP12-associated immunoreceptor, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Siglecs are cell surface proteins that bind sialic acid. They are found primarily on the surface of immune cells and are a subset of the I-type lectins. Siglec-15 consisting of immunoglobulin (Ig)-like domains, transmembrane domain and a short cytoplasmic tail. Siglec-15 is that recognizes sialylated glycans and regulates osteoclast differentiation. Siglec-15 is a potential therapeutic target for osteoporosis and plays a conserved regulatory role in the immune system of vertebrates.
- Angata T, et al. 2007. Glycobiology. 178(8):838-846.
- Yusuke K, et al. 2015. Bone. 17:217-226.
- Hiruma Y. et al. 2011. Biochem Biophys Res Commun. 409(3):424-9.